Northwest Biotherapeutics claims DCVax-L survival benefit underestimated

Dr. Marnix Bosch, Chief Technical Officer at Northwest Biotherapeutics, presented these findings at the 2026 British Neuro-Oncology Society annual meeting. The updated assessment moves beyond the cohort-level data used in the original trial, instead applying propensity score matching and inverse probability weighting to compare DCVax-L outcomes against independent randomized controlled trials.

Under these more rigorous statistical frameworks, the median survival advantage reached between 3.4 and 6.3 months, depending on the specific trial data utilized. This contrasts with the 2.8-month advantage identified in the company’s initial analysis. To ensure the robustness of these findings, independent statisticians also performed sensitivity analyses, including E Values and Rosenbaum's Gamma measures. These tests indicated that the observed clinical improvements were unlikely to be the result of hidden patient imbalances or external confounding factors.

Northwest Biotherapeutics continues to pursue regulatory pathways for DCVax-L, which is currently under review for a Marketing Authorization Application in the UK. The company maintains that these directionally consistent results reinforce the efficacy of its dendritic cell-based vaccine in treating glioblastoma, the most aggressive form of primary brain cancer.